J Clin Psychiatry. 1990 Sep;51 Suppl:31-9.

Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.

Petracca A, Nisita C, McNair D, Melis G, Guerani G, Cassano GB.

Source

Institute of Clinical Psychiatry, University of Pisa, Italy.

Abstract

The authors reviewed pharmacologic treatment of generalized anxiety disorder (GAD), particularly treatment with benzodiazepine agents, and compared the antianxiety effects and dependence risks of these agents with those of nonGABAergic compounds such as buspirone--a new psychotropic drug--in the treatment of chronic anxiety. Forty outpatients who met DSM-III criteria for GAD were randomly assigned to double-blind treatment with buspirone or lorazepam. After 8 weeks, treatment was abruptly stopped and withdrawal reactions were evaluated at Weeks 9 and 10. After 3 to 4 weeks, buspirone's efficacy in treating GAD symptomatology was found to be comparable with lorazepam's, except for sleep disturbances, which were minimally affected by buspirone. After treatment was discontinued, buspirone-treated patients were free from withdrawal symptoms, while the symptoms of lorazepam-treated patients worsened at Week 9.

PMID:: 2211564; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Medical

Anxiety - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. [J Clin Psychopharmacol. 1995]
Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study.
Delle Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. J Clin Psychopharmacol. 1995 Feb; 15(1):12-9.
[Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders]. [Encephale. 1996]
[Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
Lemoine P, Rouillon F, Pouget D. Encephale. 1996 Nov-Dec; 22(6):461-7.
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. [J Clin Psychiatry. 1999]
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR, DuPont RL, Hedges D, Haskins JT. J Clin Psychiatry. 1999 Aug; 60(8):528-35.
Review [Treatment of generalized anxiety: new pharmacologic approaches]. [Encephale. 1995]
Review [Treatment of generalized anxiety: new pharmacologic approaches].
Boulenger JP. Encephale. 1995 Nov-Dec; 21(6):459-66.
Review Buspirone in the long-term treatment of generalized anxiety disorder. [J Clin Psychiatry. 1987]
Review Buspirone in the long-term treatment of generalized anxiety disorder.
Feighner JP. J Clin Psychiatry. 1987 Dec; 48 Suppl:3-6.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treatment of generalized anxiety disorder: preliminary clinical experience with ...
Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.
J Clin Psychiatry. 1990 Sep ;51 Suppl:31-9.

PubMed
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blocka...
A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.
Vaccine. 2011 Nov 21. [Epub ahead of print]

PubMed
Immune responses in adults to revaccination with a tetanus toxoid, reduced dipht...
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose.
Vaccine. 2012 Jan 20 ;30(5):974-82. Epub 2011 Nov 21 .

PubMed
Practical considerations in the re-irradiation of recurrent and second primary h...
Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much?
Int J Radiat Oncol Biol Phys. 2011 Dec 1 ;81(5):1211-9.

PubMed
Catatonic syndrome in a general psychiatric inpatient population: frequency, cli...
Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.
J Clin Psychiatry. 1990 Sep ;51(9):357-62.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: